(Q44087054)

English

Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily

scientific article published in January 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Konopnicki D

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

De Wit S

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Poll B

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Crommentuyn K

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Huitema A

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Clumeck N

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1-6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Indinavir concentrations and antiviral effect

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00255.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2005.00255.X

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44087054&oldid=2106454583"